Allergan's loss may be J&J's gain as Spravato rival hits roadblock

7 March 2019
depression-drug-addict-large-1-

While Johnson & Johnson (NYSE: JNJ) celebrates success with its novel depression therapy Spravato (esketamine), hopes for Allergan’s (NYSE: AGN) innovative option rapastinel were struck a blow on Wednesday.

The firm had hoped to rival Spravato with a better safety profile, but negative results from three pivotal studies show the candidate is lacking in efficacy.

Shares in Allergan fell by 2.5% in post-market trading Wednesday, but recovered to $144.20 today.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical